GR1010637B - Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση - Google Patents

Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση Download PDF

Info

Publication number
GR1010637B
GR1010637B GR20230100025A GR20230100025A GR1010637B GR 1010637 B GR1010637 B GR 1010637B GR 20230100025 A GR20230100025 A GR 20230100025A GR 20230100025 A GR20230100025 A GR 20230100025A GR 1010637 B GR1010637 B GR 1010637B
Authority
GR
Greece
Prior art keywords
aqueous solution
intravenous injection
stable paracetamol
paracetamol aqueous
stable
Prior art date
Application number
GR20230100025A
Other languages
English (en)
Inventor
Ιουλια Κλεωνος Τσετη
Original Assignee
Ιουλια Κλεωνος Τσετη
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ιουλια Κλεωνος Τσετη filed Critical Ιουλια Κλεωνος Τσετη
Priority to GR20230100025A priority Critical patent/GR1010637B/el
Publication of GR1010637B publication Critical patent/GR1010637B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε συνθέσεις σταθερού υδατικού διαλύματος παρακεταμόλης για χρήση σε ενδοφλέβια έγχυση, οι οποίες περιέχουν νερό, παρακεταμόλη και ιστιδίνη.
GR20230100025A 2023-01-13 2023-01-13 Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση GR1010637B (el)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20230100025A GR1010637B (el) 2023-01-13 2023-01-13 Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20230100025A GR1010637B (el) 2023-01-13 2023-01-13 Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση

Publications (1)

Publication Number Publication Date
GR1010637B true GR1010637B (el) 2024-02-15

Family

ID=90276009

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20230100025A GR1010637B (el) 2023-01-13 2023-01-13 Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση

Country Status (1)

Country Link
GR (1) GR1010637B (el)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277546A1 (en) * 2009-07-23 2011-01-26 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
EP2389923A1 (en) * 2010-05-19 2011-11-30 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
WO2017007957A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Reduced sodium poloxamer-188 formulations and methods for use
US20180256523A1 (en) * 2007-11-13 2018-09-13 Mallinckrodt Ip Reduced dose intravenous acetaminophen
WO2019171162A1 (en) * 2018-03-06 2019-09-12 Hafeez Kalak Abdul Parenteral acetaminophen for intravenous administration fortified with amino acids and vitamin for counteracting acetaminophen induced hepatotoxicity and nephrotoxicity
US20190380950A1 (en) * 2017-01-24 2019-12-19 Woosung Pharmaceutical Co., Ltd. Injection composition containing acetaminophen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180256523A1 (en) * 2007-11-13 2018-09-13 Mallinckrodt Ip Reduced dose intravenous acetaminophen
EP2277546A1 (en) * 2009-07-23 2011-01-26 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
EP2389923A1 (en) * 2010-05-19 2011-11-30 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
WO2017007957A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Reduced sodium poloxamer-188 formulations and methods for use
US20190380950A1 (en) * 2017-01-24 2019-12-19 Woosung Pharmaceutical Co., Ltd. Injection composition containing acetaminophen
WO2019171162A1 (en) * 2018-03-06 2019-09-12 Hafeez Kalak Abdul Parenteral acetaminophen for intravenous administration fortified with amino acids and vitamin for counteracting acetaminophen induced hepatotoxicity and nephrotoxicity

Similar Documents

Publication Publication Date Title
RU2010131179A (ru) Жидкая композиция, содержащая антитело высокой концентрации
TN2018000443A1 (en) Stable liquid pharmaceutical preparation
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MX2018006486A (es) Composiciones para el cuidado bucal.
TN2017000348A1 (en) Novel proteins specific for pyoverdine and pyochelin
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
EA201791579A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2 адренергических рецепторов
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
PH12021550832A1 (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
EA202190878A1 (ru) Составы на основе антитела к fgfr2
MX2022000811A (es) Inhibidores de enzimas.
MX2022002069A (es) Inhibidores de enzimas.
EA201690626A1 (ru) Новый состав гонадотропинов
GR1010637B (el) Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση
MX2022010960A (es) Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.
MX2019005022A (es) Composiciones para el cuidado bucal.
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2023000198A (es) Inhibidores de atr y usos de estos.
MX2018007377A (es) Composicion de acido hialuronico para inyecciones en el pene.
ZA202000085B (en) Biphasic oral care compositions
MX2020002606A (es) Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso.
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
MX2020006003A (es) Composiciones para el cuidado bucal.

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20240312